Skip to main content
SpringerPlus

Table 2 Treatment outcomes

From: A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study

Outcomes

No. of patients (n = 53)a

95 % confidence interval

Response

  

Complete response

1

 

Partial response

24

 

Stable disease

22

 

Progressive disease

2

 

Not evaluable

4

 

Response rate (%)

25 (47.1 %)

33.7–60.6

Disease control rate (%)

47 (88.7 %)

80.1–97.2

  1. aResponse rate and disease control rate were analyzed for the patients with assessable lesion
Back to article page